Cumberland Pharmaceuticals
CPIX
44 hedge funds and large institutions have $23.6M invested in Cumberland Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 12 increasing their positions, 10 reducing their positions, and 7 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 10
1% more capital invested
Capital invested by funds: $23.4M → $23.6M (+$204K)
8% less funds holding
Funds holding: 48 → 44 (-4)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$590K |
| 2 |
New York State Common Retirement Fund
Albany,
New York
|
+$95.7K |
| 3 |
AI
Ariel Investments
Chicago,
Illinois
|
+$73K |
| 4 |
Renaissance Technologies
New York
|
+$58.2K |
| 5 |
EGA
Eagle Global Advisors
Houston,
Texas
|
+$30.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$218K |
| 2 |
SLG
Stanley-Laman Group
Berwyn,
Pennsylvania
|
-$158K |
| 3 |
CCM
Coldstream Capital Management
Bellevue,
Washington
|
-$70K |
| 4 |
PP
PDT Partners
New York
|
-$68K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$60K |
CPIX Hedge Fund Activity: Q2 2016 in Review
44 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Cumberland Pharmaceuticals (CPIX) for Q2 2016, worth a combined $23.6M — up 0.87% from $23.4M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of CPIX and 4 opened new positions — a net loss of 3 holders — while 10 trimmed existing stakes and 12 added.
The largest buyer was Stonepine Capital Management, opening a new position worth an estimated $590K. The largest seller was BlackRock Institutional Trust, cutting an estimated $218K.
- 44 institutional investors held Cumberland Pharmaceuticals (CPIX) as of Q2 2016, down from 48 in Q1 2016.
- Funds reported $23.6M of Cumberland Pharmaceuticals stock for Q2 2016, up 0.87% quarter-over-quarter.
- 4 funds opened new Cumberland Pharmaceuticals positions in Q2 2016 and 7 closed out, a net change of -3 holders.
- The largest Cumberland Pharmaceuticals buyer in Q2 2016 was Stonepine Capital Management, an estimated $590K added.
- The largest Cumberland Pharmaceuticals seller in Q2 2016 was BlackRock Institutional Trust, an estimated $218K sold.
Based on aggregated 13F filings for Q2 2016.